Last checked at 
LONDON (Alliance News) - PureTech Health PLC on Friday said its Gelesis portfolio company has presented positive data about its hydrogel platform at the ObesityWeek 2016 conference in Louisiana, US.
Data from the first in-human study of Gelesis200, Gelesis's second product candidate for weight management and glycaemic control, demonstrated taking the drug 10 minutes before a meal increased fullness throughout the entire day.
"These clinical results for both Gelesis100 and Gelesis200 represent an important step forward in weight management and glycaemic control in people who are overweight or have obesity as well as those who have prediabetes or type 2 diabetes. We look forward to advancing the Gelesis hydrogel engineering platform to address important medical needs," said PureTech Chief Scientifi Officer Joe Bolen.
PureTech owns 23% of Gelesis.
Shares in PureTech were up 1.9% to 132.50 pence on Friday.
By Sam Unsted; samunsted@alliancenews.com; @SamUAtAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.
